Tumour-associated trypsin inhibitor and tumour-associated trypsin

References

• Finnish Cancer Registry Cancer incidence in Finland 1982. Cancer Society of Finland, Helsinki 1986, Publication no, 34
   Google Scholar
• Skarzynski B., Sarnecka-Keller M. Peptides in human urine. Adv Clin Chem 1962; 5: 107–34
   PubMedGoogle Scholar
• Stenman U-H, Pesonen K., Huhtala M-L. Rapid concentration of urinary peptides and proteins. Anal Biochem 1982; 123: 53–7
   Google Scholar
• Stenman U-H, Huhtala M-L, Koistinen R., Seppälä M. Immunochemical demonstration of an ovarian cancer associated urinary peptide. Int J Cancer 1982; 30: 53–7
   PubMed Web of Science ®Google Scholar
• Huhtala M-L, Pesonen K., Kalkkinen N., Stenman U-H. Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 1982; 257: 13713–6
   PubMed Web of Science ®Google Scholar
• Halila H., Huhtala M-L, Schroder T., Kiviluoto T., Stenman U-H. Pancreatic secretory trypsin inhibitor in pancreatectomized patients. Clin Chim Acta 1985; 153: 209–16
   PubMed Web of Science ®Google Scholar
• Yamamoto T., Nakamura Y., Nishide T., Emi M., Ogawa M., Mori T., Matsubara K. Molecular cloning and nucleotide sequence of human pancreatic secretory trypsin inhibitor (PSTI) cDNA. Biochem Biophys Res Commun 1985; 132: 605–12
   PubMedGoogle Scholar
• Kikuchi N., Nagata K., Yoshida N., Ogawa M. The multiplicity of human pancreatic secretory trypsin inhibitor. J Biochem 1985; 98: 679–94
   Google Scholar
• Eddeland A., Ohlsson K. A radioimmunoassay for measurement of human pancreatic secretory trypsin inhibitor in different body fluids. Hoppe-Seyler's Z Physiol Chem 1978; 359: 671–5
   PubMedGoogle Scholar
• Kitahara T., Takatsuka Y., Fujimoto K-I, Tanaka S., Ogawa M., Kosaki K. Radioimmunoassay for human pancreatic secretory trypsin inhibitor: Measurement of serum pancreatic secretory trypsin inhibitor in normal subjects and subjects with pancreatic diseases. Clin Chim Acta 1980; 103: 135–43
   PubMed Web of Science ®Google Scholar
• Huhtala M-L, Kahanpää K., Seppälä M., Halila H., Stenman U-H. Excretion of a tumor associated trypsin inhibitor (TATI) into urine of patients with gynecological malignancy. Int J Cancer 1983; 31: 711–4
   PubMed Web of Science ®Google Scholar
• Kolho K-L, Huhtala M-L, Jalanko H., Rauramo I., Stenman U-H. Pancreatic secretory trypsin inhibitor from human amniotic fluid and fetal and neonatal urine: concentrations and physicochemical characterization. Clin Chim Acta 1986; 156: 123–30
   PubMedGoogle Scholar
• Halila H., Lehtovirta P., Stenman U-H. Tumor-associated trypsin inhibitor in ovarian cancer. Br J Cancer 1988; 57: 304–7
   PubMed Web of Science ®Google Scholar
• von Fritz H., MÜller I., Wiedemann M., Werle E. Zur Chemie und Physiologie der spezifischen Trypsininhibitoren aus den BauchspeicheldrÜsen von Rind, Hund, Schwein und Mensch. Hoppe-Seyler's Z Physiol Chem 1967; 348: 405–18
   PubMedGoogle Scholar
• Murata M., Ogawa M., Matsuda K., Matsuura N., Kosaki G. Immunoreactive pancreatic secretory trypsin inhibitor in gynecological diseases. Res Commun Chem Pathol Pharmacol 1983; 41: 493–9
   PubMedGoogle Scholar
• Mogensen O., Mogensen B., Jakobsen A. TATI and CA 125 in mucinous ovarian cancer. Ecco Meeting. London 1989, (Abstract)
   Google Scholar
• Bast R. CJ, Klug T. L., St John E., et al. A radio-immunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–7
   PubMed Web of Science ®Google Scholar
• Stenman U-H, Koivunen E., Itkonen O., Turpeinen U., Halila H., Huhtala M-L. Tumor-associated trypsin inhibitor, TATI. Clinical use and biological function. Ann Chir Gynaecol Ferm 1989; 78: 77–82
   Google Scholar
• Haglund C., Huhtala M-L, Halila H., Nordling S., Roberts P., Scheinin T., Stenman U-H. Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary disease. Brit J Cancer 1986; 54: 297–303
   PubMedGoogle Scholar
• Matsuda K., Ogawa M., Murata A., Kitahara T., Kosaki G. Elevation of serum immunoreactive pancreatic secretory trypsin inhibitor contents in various malignant diseases. Res Commun Chem Pathol Pharmacol 1983; 40: 301–5
   PubMedGoogle Scholar
• Ogawa M., Kitahara T., Fujimoto K., Tanaka S., Takatsuka Y., Kosaki G. Serum pancreatic secretory trypsin inhibitor in acute pancreatitis. Lancet 1980; 2: 205
   PubMed Web of Science ®Google Scholar
• Yedema C., Kenemans P., Wobbes T., Rood up't E., Poels L. G., Verheijen R., Thomas C. Tumour-associated antigens in surgical and gynaecological cancer (Abstr). Ann Clin Biochem 1987; 24(Suppl 2)56
   Google Scholar
• Rayo J. I., Talavera J. RG, Martin M., Munoz A., Martin R., Canizo A., Soler J. J. Evaluation of serum TATI levels in head and neck cancer. XVI International ISOBM Congress, Barcelona, September, 1988, Abstract PF7
   Google Scholar
• Lasson Å, Borgström A., Ohlsson K. Elevated pancreatic secretory trypsin inhibitor levels during severe inflammatory disease, renal insufficiency, and after various surgical procedures. Scand J Gastroenterol 1986; 21: 1275–80
   PubMed Web of Science ®Google Scholar
• Ogawa M., Matsuda K., Shibata T., Matsuda Y., Ukai T., Ohta M., Mori T. Elevation of serum pancreatic secretory trypsin inhibitor (PSTI) in patients with serious injury. Res Commun Chem Pathol Pharmacol 1985; 50: 259–66
   PubMedGoogle Scholar
• Ogawa M. Pancreatic secretory trypsin inhibitor as an acute phase reactant. Clin Biochem 1988; 21: 19–25
   PubMed Web of Science ®Google Scholar
• Paavonen J., Lehtinen M., Lehto M., Laine S., Aine R., Räsänen L., Stenman U-H. Concentrations of tumor-associated trypsin inhibitor and C-reactive protein in serum in acute pelvic inflammatory disease. Clin Chem 1989; 35: 869–71
   PubMed Web of Science ®Google Scholar
• Halila H., Huhtala M-L, Haglund C., Nordling S., Stenman U-H. Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA. Br J Cancer 1987; 56: 153–6
   PubMed Web of Science ®Google Scholar
• Ogawa M., Matsuura N., Higashiyma K., Mori T. Expression of pancreatic secretory trypsin inhibitor in various cancer cells. Res Commun Chem Pathol Pharmacol 1987; 55: 137–40
   PubMedGoogle Scholar
• Matsuda K., Ogawa M., Shibata T., Nishibe S., Miyauchi K., Matsuda Y., Mori T. Postoperative elevation of serum pancreatic secretory trypsin inhibitor. Am J Gastroenterol 1985; 80: 694–8
   PubMed Web of Science ®Google Scholar
• Murata M., Ogawa M., Uda K-I, et al. Release of pancreatic secretory trypsin inhibitor from human hepatoblastoma cells on stimulation with cytokines. Life Sci 1988; 43: 1233–40
   PubMedGoogle Scholar
• Kazal L. A., Spicer D. S., Brahinsky R. AA. Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Amer Chem Soc 1948; 70: 3034–40
   PubMed Web of Science ®Google Scholar
• Shibata T., Ogawa M., Matsuda K., Miyauchi K., Yamamoto T., Mori T. Purification and characterization of pancreatic secretory trypsin inhibitor in human gastric mucosa. Clin Chim Acta 1986; 159: 27–36
   PubMedGoogle Scholar
• Barbey-Morel C., Pierce J. A., Campbell D. H. Lipopolysacharide modulates the expression of alpha 1 proteinase inhibitor and other proteinase inhibitors in human monocytes and macrophages. J Exp Med 1987; 166: 104–54
   Google Scholar
• Huhtala M-L. Demonstration of a new acrosin inhibitor in human seminal plasma. Hoppe-Seyler's Z Physiol Chem 1984; 365: 819–25
   PubMedGoogle Scholar
• Turpeinen U., Koivunen E., Stenman U-H. Reaction of a tumor-associated trypsin inhibitor with serine proteases involved in tumor invasion. Biochem J 1988; 254: 911–4
   PubMedGoogle Scholar
• Hunt L. T., Barker W. C., Dayhoff M. O. Epidermal growth factor: Internal duplication and probable relationship to pancreatic secretory trypsin inhibitor. Biochem Biophys Res Comm 1974; 60: 1020–8
   PubMedGoogle Scholar
• Ogawa M., Tsushima T., Ohba Y., Ogawa N., Tanaka S., Ishida M., Mori T. Stimulation of DNA synthesis in human fibroblasts by human pancreatic secretory trypsin inhibitor. Res Commun Chem Pathol Pharmacol 1985; 50: 155–8
   PubMedGoogle Scholar
• Niinobu T., Ogawa M., Shibata T., Murata A., Nishibe S., Mori T., Ogata N. Specific binding of human pancreatic secretory trypsin inhibitor to various cultured cells. Res Commun Chem Pathol Pharmacol 1986; 53: 245–8
   PubMedGoogle Scholar
• McKeehan W. L., Sakagami Y., Hoshi H., McKeehan K. A. Two apparent human endothelial cell growth factors from human hepatoma cells are tumor-associated proteinase inhibitors. J Biol Chem 1986; 261: 5378–83
   PubMed Web of Science ®Google Scholar
• Horii A., Kobayashi T., Tomita N., et al. Primary structure of human pancreatic secretory trypsin inhibitor (PSTI) gene. Biochem Biophys Res Comm 1987; 149: 635–41
   PubMedGoogle Scholar
• Pubols M. H., Bartelt D. C., Greene L. J. Trypsin inhibitor from human pancreas and pancreatic juice. J Biol Chem 1974; 249: 2235–42
   PubMed Web of Science ®Google Scholar
• Stenman U-H, Koivunen E., Vuento M. Characterization of a tumor-associated serine protease. Biol Chem Hoppe-Seyler. 1988; 369: 9–14
   PubMedGoogle Scholar
• Sträuli P. A concept of tumor invasion. Proteinases and tumor invasion, P. BA Sträuli, A. Barci. Raven Press, New York 1980; 1–15, 1980
   Google Scholar
• Koivunen E., Huhtala M-L, Stenman U-H. Human ovarian tumor-associated trypsin. Its purification from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem 1989; 264: 14095–9
   PubMed Web of Science ®Google Scholar
• Emi M., Nakamura Y., Ogawa M., Yamamoto T., Nishide T., Mori T., Matsubara K. Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene 1986; 41: 305–10
   PubMed Web of Science ®Google Scholar
• Itkonen O., Koivunen E., Hurme M., Alfthan H., Schroder T., Stenman U-H. Time-resolved immunofluorometric assays for trypsinogen-1 and-2 reveal preferential elevation of trypsinogen-2 in pancreatitis. J Clin Lab Med, (in press)
   Google Scholar
• Koivunen E., Itkonen O., Stenman U-H. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. Cancer Res, (in press)
   Google Scholar
• Mignatti P., Robbins E., Rifkin B. Tumor invasion through the human amniotic membrane: requirement for a protease cascade. Cell 1986; 47: 487–98
   PubMed Web of Science ®Google Scholar
• Mullins E., Rohrlich S. The role of proteinases in cellular invasiveness. Biochem Biophys Acta 1983; 695: 177–214
   PubMed Web of Science ®Google Scholar
• Danø K., Andreasen P. A., Gröndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139–266
   PubMed Web of Science ®Google Scholar
• Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35–65
   PubMed Web of Science ®Google Scholar
• Liotta L. A., Rao C. N., Barsky S. H. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49: 636–49
   PubMed Web of Science ®Google Scholar
• Tryggvason K., Höyhtyä M., Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987; 907: 191–217
   PubMed Web of Science ®Google Scholar
• Gruber B. L., Marchese M. J., Suzuki K., Schwartz L. B., Okada Y., Nagase H., Ramamurthy N. S. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest 1989; 84: 1657–62
   PubMed Web of Science ®Google Scholar
• Sporn M. B., Roberts A. B. Peptide growth factors and inflammation, tissue repair, and cancer. J Clin Invest 1986; 78: 329–32
   PubMed Web of Science ®Google Scholar